New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
09:03 EDTITMNInterMune rises after Boehringer Ingelheim IPF trials hit primary endpoints
Boehringer Ingelheim’s INPULSIS-1 and -2 trials for nintedanib as a treatment for idiopathic pulmonary fibrosis, or IPF, showed that nintedanib 150 mg twice daily slowed disease progression by significantly reducing rate of decline in FVC and was associated with an acceptable side-effect profile, according to an abstract posted to the site of the American Thoracic Society. The Fly notes that InterMune is also developing a treatment for IPF. Shares of InterMune are up 8.7% to $35.71 in pre-market trading. Reference Link
News For ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ITMN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use